Tempus AI (NASDAQ: TEM) stock is soaring 5.09% in pre-market trading on Monday following the announcement of its new AI-powered target discovery and validation platform, Tempus Loop. The platform aims to revolutionize oncology research and drug development by integrating real-world patient data with advanced biological modeling and CRISPR screens.

Tempus Loop addresses a significant challenge in the pharmaceutical industry: the high failure rate of preclinical assets in becoming real-world medicines. By leveraging Tempus' vast multimodal data library and AI capabilities, the platform promises to accelerate novel target identification and validation, potentially reducing the time and cost of drug discovery.

Kate Sasser, Chief Scientific Officer at Tempus, highlighted the platform's potential, stating, "With Loop, we have integrated vast multimodal patient data, which includes outcome data, with more relevant human biological models and high-throughput functional screens, all wrapped with AI tooling, to ultimately help find new patient cohorts of interest and unique and clinically relevant targets." The company has already successfully deployed Loop for a large pharmaceutical company, validating drug targets within a year – a significant acceleration of the standard discovery timeline.